uniQure N.V. (QURE) Stock Analysis and Metrics

uniQure

NASDAQ: QURE

$39.00 ▼ -0.43 (-1.09%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.42 Bn

P/E-15.72

P/S133.98

Div. Yield0.00

Total Debt (Qtr)49.94 Mn

Add ratio to table…

About

uniQure N. V. is a clinical-stage gene therapy company focused on developing single-treatment, potentially curative therapies for patients with rare and severe genetic diseases. Operating at the forefront of the gene therapy industry, the company leverages its proprietary adeno-associated virus (AAV) vector platform to design and deliver gene-based treatments targeting neurodegenerative, neuromuscular, and metabolic disorders. uniQure’s pipeline prioritizes diseases with high unmet medical needs, including Huntington’s disease, refractory mesial temporal lobe epilepsy, Fabry disease, and amyotrophic lateral sclerosis caused by SOD1 mutations.

The company generates revenue primarily through collaborations, licensing agreements, and milestone payments tied to the development and commercialization of its gene therapy candidates. Its most advanced commercial product, HEMGENIX (etranacogene dezaparvovec), a gene therapy for hemophilia B, is exclusively licensed to CSL Behring, which handles global commercialization. uniQure receives royalties on net sales of HEMGENIX and is eligible for additional milestone payments based on regulatory and commercial achievements. The company also secures funding through public offerings, debt facilities, and research grants to support its clinical programs and manufacturing capabilities.

The company operates through the following segments:

• Neurodegenerative Disease Programs: This segment focuses on developing gene therapies for severe neurological disorders, including Huntington’s disease (AMT-130) and amyotrophic lateral sclerosis caused by SOD1 mutations (AMT-162). AMT-130, a microRNA-based therapy delivered via AAV5, aims to silence the mutant huntingtin gene and has demonstrated statistically significant slowing of disease progression in clinical trials. The program has received Breakthrough Therapy, RMAT, Orphan Drug, and Fast Track designations from the FDA. AMT-162, an intrathecally administered therapy for SOD1-ALS, is currently paused pending further safety evaluations following a dose-limiting toxicity observed in a Phase I/II trial.

• Neurological Disorder Programs: This segment includes AMT-260, a gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE). AMT-260 uses an AAV9 vector to deliver engineered microRNAs targeting the GRIK2 gene, aiming to suppress seizure activity. The program is in Phase I/II clinical trials, with initial data showing a substantial reduction in seizure frequency in treated patients. The therapy has been granted Orphan Drug designation by the FDA.

• Metabolic Disease Programs: This segment centers on AMT-191, a gene therapy for Fabry disease, a lysosomal storage disorder caused by a deficiency in the α-galactosidase A enzyme. AMT-191 employs an AAV5 vector to deliver a functional GLA transgene, enabling sustained enzyme production. The therapy has shown dose-dependent increases in enzyme activity in early-stage clinical trials and has received Orphan Drug and Fast Track designations from the FDA. Enrollment in higher-dose cohorts is currently paused due to liver enzyme elevations observed in some patients.

• Technology and Manufacturing Platforms: This segment encompasses uniQure’s proprietary AAV vector engineering, manufacturing, and gene silencing technologies, including miQURE, linQURE, and GoQURE platforms. These platforms enable the development of next-generation gene therapies with improved safety, efficacy, and tissue-specific targeting. The company also operates a state-of-the-art manufacturing facility and collaborates with third-party contract manufacturers to support its clinical and commercial supply needs.

uniQure holds a competitive position in the gene therapy industry, distinguished by its deep expertise in AAV vector design, scalable manufacturing capabilities, and a robust intellectual property portfolio. The company faces competition from large pharmaceutical and biotechnology firms, including Novartis, Roche, Wave Life Sciences, and Alnylam Pharmaceuticals, as well as smaller specialized players like Sarepta Therapeutics and 4D Molecular Therapeutics. uniQure’s competitive advantages include its proprietary miQURE gene-silencing platform, which enables precise targeting of disease-causing genes, and its baculovirus-based manufacturing system, which allows for efficient and scalable production of AAV vectors. The company’s focus on rare diseases with limited treatment options further strengthens its market positioning, as it aims to be a first-mover in indications with significant unmet needs.

uniQure’s customer base primarily consists of patients suffering from rare genetic diseases, as well as healthcare providers and institutions involved in their treatment. The company’s commercialized product, HEMGENIX, is marketed by CSL Behring to hemophilia B patients, while its clinical-stage therapies target individuals with Huntington’s disease, refractory epilepsy, Fabry disease, and SOD1-ALS. uniQure collaborates with academic research institutions, regulatory agencies, and industry partners to advance its pipeline, and its therapies are administered in specialized clinical settings, including hospitals and gene therapy treatment centers.

Investment Thesis

▲ Bull case

uniQure's core competitive advantage lies in its robust and unique natural history dataset derived from the Enroll-HD platform, which tracks over 30,000 Huntington's disease patients globally and provides contemporaneous, high-fidelity clinical data that could serve as a scientifically valid external control for regulatory submissions. Management emphasized during the Q&A that this resource is "generously provided" by the HD community and represents a "treasure trove" that could mitigate the ethical and practical burdens of a sham-controlled trial, particularly given the disease's slow progression and the invasive nature of the neurosurgical procedure required for AMT-130 delivery. The company has consistently maintained that biomarker signals such as neurofilament light (NfL) and volumetric MRI changes have strengthened over time, with no disease-related safety events observed since December 2022, suggesting a durable and biologically plausible treatment effect that aligns with mechanistic expectations for a one-time CNS gene therapy. This positions uniQure to potentially negotiate a flexible Phase 3 design with the FDA that leverages real-world evidence, reducing patient burden and accelerating timelines compared to conventional sham-controlled studies, especially if interim biomarker analysis supports an accelerated approval pathway—a concept the FDA previously verbally communicated as possible and which remains under discussion. The ex-U.S. regulatory strategy, including active engagement with the MHRA and EMA for named-patient and early access programs, presents a significant but underappreciated catalyst, as success in European or UK markets could generate early revenue, validate commercial readiness, and de-risk the U.S. approval path by demonstrating real-world effectiveness in diverse healthcare systems. Furthermore, the company's strengthened balance sheet—bolstered by $404.2 million in recent capital raises—provides a cash runway into 2029, affording ample time to navigate regulatory complexities, advance pipeline programs like AMT-260 (epilepsy) and AMT-191 (Fabry), and potentially pursue independent U.S. commercialization of AMT-130 without dilutive partnerships, preserving long-term value creation for shareholders. The growing patient advocacy engagement and site interest following the September data publication further support feasible trial enrollment, addressing a key operational risk often underestimated by the market in rare disease neurosurgical trials.

uniQure's core competitive advantage lies in its robust and unique natural history dataset derived from the Enroll-HD platform, which tracks over 30,000 Huntington's disease patients globally and provides contemporaneous, high-fidelity clinical data that could serve as a scientifically valid external control for regulatory submissions. Management emphasized during the Q&A that this resource is "generously provided" by the HD community and represents a "treasure trove" that could mitigate the ethical and practical burdens of a sham-controlled trial, particularly given the disease's slow progression and the invasive nature of the neurosurgical procedure required for AMT-130 delivery. The company has consistently maintained that biomarker signals such as neurofilament light (NfL) and volumetric MRI changes have strengthened over time, with no disease-related safety events observed since December 2022, suggesting a durable and biologically plausible treatment effect that aligns with mechanistic expectations for a one-time CNS gene therapy. This positions uniQure to potentially negotiate a flexible Phase 3 design with the FDA that leverages real-world evidence, reducing patient burden and accelerating timelines compared to conventional sham-controlled studies, especially if interim biomarker analysis supports an accelerated approval pathway—a concept the FDA previously verbally communicated as possible and which remains under discussion. The ex-U.S. regulatory strategy, including active engagement with the MHRA and EMA for named-patient and early access programs, presents a significant but underappreciated catalyst, as success in European or UK markets could generate early revenue, validate commercial readiness, and de-risk the U.S. approval path by demonstrating real-world effectiveness in diverse healthcare systems. Furthermore, the company's strengthened balance sheet—bolstered by $404.2 million in recent capital raises—provides a cash runway into 2029, affording ample time to navigate regulatory complexities, advance pipeline programs like AMT-260 (epilepsy) and AMT-191 (Fabry), and potentially pursue independent U.S. commercialization of AMT-130 without dilutive partnerships, preserving long-term value creation for shareholders. The growing patient advocacy engagement and site interest following the September data publication further support feasible trial enrollment, addressing a key operational risk often underestimated by the market in rare disease neurosurgical trials.

▼ Bear case

uniQure faces a fundamental and likely insurmountable regulatory hurdle with the FDA, which has consistently rejected the validity of its external control approach using Enroll-HD data, asserting that such comparisons are "post hoc" and "distorted" despite the company's claims of contemporaneous, high-quality natural history comparisons. Senior FDA officials have publicly characterized AMT-130 as a "failed product," citing a prior placebo-controlled study that was "stone cold negative," and maintaining that the agency has never accepted non-randomized, non-sham-controlled designs for Huntington’s disease therapies in its 25-year history, directly contradicting uniQure's belief in regulatory flexibility for rare, progressive CNS disorders. The ethical and practical concerns surrounding a sham-controlled trial—requiring patients to undergo invasive neurosurgery (including burr holes and potential superficial skull drilling) without therapeutic benefit for extended periods—are not merely theoretical; patient advocacy groups have warned that a two-year control arm period represents active, irreversible neurodegeneration, potentially moving patients beyond the therapeutic window where AMT-130 could meaningfully preserve function, thereby undermining the trial's scientific validity and ethical defensibility. This regulatory impasse is compounded by the lack of clarity on Phase 3 design, timeline, and investment requirements, with management acknowledging it is "premature" to discuss costs or enrollment feasibility, creating significant uncertainty around the capital efficiency of the AMT-130 program despite the strengthened cash position. Meanwhile, competing approaches such as PTC's oral votoplam for Huntington’s disease—which avoids neurosurgery entirely—pose a growing threat to uniQure's first-mover advantage, especially if delayed approval allows superior alternatives to capture market share in a disease area with no current disease-modifying therapies. The epilepsy program (AMT-260), while progressing toward Q2 six-month data, remains in early Phase 1 with no established efficacy benchmarks, and the Fabry program (AMT-191) lacks meaningful near-term milestones, leaving the company overly dependent on a single, high-risk asset (AMT-130) navigating a hostile regulatory environment where the FDA's skepticism appears entrenched and unresponsive to scientific arguments about biomarker durability or natural history validity.

uniQure faces a fundamental and likely insurmountable regulatory hurdle with the FDA, which has consistently rejected the validity of its external control approach using Enroll-HD data, asserting that such comparisons are "post hoc" and "distorted" despite the company's claims of contemporaneous, high-quality natural history comparisons. Senior FDA officials have publicly characterized AMT-130 as a "failed product," citing a prior placebo-controlled study that was "stone cold negative," and maintaining that the agency has never accepted non-randomized, non-sham-controlled designs for Huntington’s disease therapies in its 25-year history, directly contradicting uniQure's belief in regulatory flexibility for rare, progressive CNS disorders. The ethical and practical concerns surrounding a sham-controlled trial—requiring patients to undergo invasive neurosurgery (including burr holes and potential superficial skull drilling) without therapeutic benefit for extended periods—are not merely theoretical; patient advocacy groups have warned that a two-year control arm period represents active, irreversible neurodegeneration, potentially moving patients beyond the therapeutic window where AMT-130 could meaningfully preserve function, thereby undermining the trial's scientific validity and ethical defensibility. This regulatory impasse is compounded by the lack of clarity on Phase 3 design, timeline, and investment requirements, with management acknowledging it is "premature" to discuss costs or enrollment feasibility, creating significant uncertainty around the capital efficiency of the AMT-130 program despite the strengthened cash position. Meanwhile, competing approaches such as PTC's oral votoplam for Huntington’s disease—which avoids neurosurgery entirely—pose a growing threat to uniQure's first-mover advantage, especially if delayed approval allows superior alternatives to capture market share in a disease area with no current disease-modifying therapies. The epilepsy program (AMT-260), while progressing toward Q2 six-month data, remains in early Phase 1 with no established efficacy benchmarks, and the Fabry program (AMT-191) lacks meaningful near-term milestones, leaving the company overly dependent on a single, high-risk asset (AMT-130) navigating a hostile regulatory environment where the FDA's skepticism appears entrenched and unresponsive to scientific arguments about biomarker durability or natural history validity.

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Products and Services Breakdown of Revenue (2025)

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Products and Services Breakdown of Revenue (2025)

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password